Allogene Therapeutics SEC filings document the regulatory record of a clinical-stage biotechnology company developing allogeneic CAR T product candidates. The filings cover material-event reports, operating and financial updates, common stock registration and offering activity, and clinical disclosures involving programs such as cema-cel in large B-cell lymphoma and ALLO-329 in autoimmune disease.
Allogene's proxy materials describe annual meeting proposals, shareholder voting matters, board governance, executive compensation, and equity award disclosures. Other filings address Nasdaq-listed common stock, capital-structure changes, material agreements, and risk factors tied to research and development, clinical execution, regulatory matters, intellectual property, and licensed gene-editing technology used in its allogeneic CAR T programs.
Allogene Therapeutics (ALLO) reported an insider transaction by its SVP and Chief Technical Officer on a Form 4. On 11/17/2025, the executive sold 786 shares of common stock at a weighted average price of $1.22 per share, with individual trade prices ranging from $1.22 to $1.23. The filing explains that these shares were sold solely to cover tax withholding obligations triggered by the vesting of restricted stock units under the company’s equity incentive plan, and that this was a mandated "sell to cover" transaction rather than a discretionary sale. Following this small sale, the reporting person beneficially owns 217,721 shares of Allogene common stock.
Allogene Therapeutics (ALLO) reported Q3 2025 results showing a narrower net loss of $41.4 million versus $66.3 million a year ago as operating expenses fell to $44.9 million from $71.8 million. Interest and other income contributed $3.5 million in the quarter.
Liquidity and runway: Cash, cash equivalents and investments were $277.1 million as of September 30, 2025, and management stated these resources are expected to fund operations for at least 12 months from the filing date. Net cash used in operating activities was $121.6 million for the nine months ended September 30, 2025.
Capital actions and structure: The company sold 7,477,047 shares via its ATM in the nine months ended September 30, 2025, generating $14.5 million in net proceeds. Shares issued and outstanding were 223,163,672 as of September 30, 2025; 224,730,144 were outstanding as of November 4, 2025.
Operations and costs: R&D expense was $31.2 million in Q3 (down from $44.7 million), and G&A was $13.7 million (down from $16.3 million). Year-to-date impairment of long-lived assets was $2.4 million, including effects related to subleased facilities. A workforce reduction approved in May 2025 (approximately 28%) resulted in $4.7 million of charges year-to-date.
Programs and funding: The company received $9.2 million to date under the CIRM award tied to ALLO‑316, recorded as a liability; related interest expense was $0.8 million year-to-date.
Allogene Therapeutics (ALLO) furnished an 8‑K stating it provided a corporate update and announced financial results for the quarter ended September 30, 2025. The details are contained in a press release attached as Exhibit 99.1.
The information was furnished under Item 2.02 and is not deemed “filed” under Section 18 of the Exchange Act, nor incorporated by reference unless specifically stated. Common stock trades on Nasdaq under ALLO.
Allogene Therapeutics (ALLO) reported an insider transaction by its Chief Financial Officer. On 10/21/2025, the CFO sold 36,744 shares of common stock at $1.2565 per share. The filing states this was a mandated sell-to-cover to satisfy tax withholding from restricted stock unit vesting and not a discretionary trade.
Following the transaction, the CFO beneficially owned 1,276,796 shares directly. The holdings include shares acquired via the employee stock purchase program: 6,000 shares on March 14, 2025 and 6,000 shares on September 15, 2025.
Allogene Therapeutics reported continued operating losses while preserving a multi-quarter cash runway as it refocuses clinical priorities. The company recorded a net loss of $50.9 million for the quarter and $110.7 million year-to-date, driven by research and development and general and administrative expenses, although total operating expenses declined versus prior-year periods. Cash, cash equivalents and investments totaled $302.6 million as of June 30, 2025, and management expects funding into the second half of 2027. The company completed a ~28% workforce reduction, recording related severance and impairment charges, and recognized impairment on a to-be-sublet leased facility and certain equipment.
Clinical updates include RMAT designation and positive signal durability for ALLO-316, IND clearance and trial initiation for ALLO-329 (RESOLUTION), and a consequential change in the ALPHA3 trial lymphodepletion approach: the FCA arm was closed after a Grade 5 adverse event attributed to ALLO-647 and standard fludarabine/cyclophosphamide (FC) was selected as the lymphodepletion regimen. The company received $9.2 million under an amended CIRM award recorded as a liability.
Allogene Therapeutics, Inc. filed a current report to note that it has released a corporate update and its financial results for the quarter ended June 30, 2025. The details are contained in a press release dated August 13, 2025, which is included as Exhibit 99.1 and incorporated by reference.
The company specifies that this information is being furnished under the rules of the Securities Exchange Act and is not deemed filed for liability purposes. The filing is signed by President and Chief Executive Officer David Chang, M.D., Ph.D.
The Schedule 13G/A discloses that Dr. Arie Belldegrun beneficially owns 12,605,894 shares of Allogene Therapeutics common stock, representing 5.7% of the class based on 218,730,809 shares outstanding. The reported holdings include 3,243,004 shares issuable within 60 days upon exercise of stock options and equity held through related entities: Bellco Legacy IV LLC (4,710,120), Bellco Legacy LLC (539,867), Vida Ventures LLC (1,798,163), Vida Ventures III, L.P. (1,720,172) and Vida Ventures III-A, L.P. (3,965).
Dr. Belldegrun disclaims beneficial ownership of the shares held by the Vida entities except to the extent of any pecuniary interest. The filing reports both sole and shared voting and dispositive powers for the aggregate position as set forth on the cover pages.
Allogene Therapeutics' Schedule 13G/A shows that David D. Chang, M.D., Ph.D., and related family trusts report combined beneficial ownership of 11,136,728 shares of common stock, representing 5.0% of the class. The filing states that this total includes 5,413,414 shares issuable upon exercise of options exercisable within 60 days, and breaks out voting and dispositive power as 8,223,532 shares sole and 2,913,196 shares shared. Separate trusts—the Chang 2006 Family Trust, JEC 2019 Trust and RTC 2019 Trust—report holdings of 1,201,108, 856,044 and 856,044 shares respectively, representing 0.5% and two 0.4% stakes. The percentage is calculated using 218,730,809 shares outstanding as disclosed by the issuer.